Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-406

I'm just stating my recollection of msb's previous position on clip. as to why, well potentially because the end point is fluffier than other trials ie chf you can measure cardiac events, death - for clbp, the trial is looking at something more subjective

to clarify I don't think all msb studies need a second trial - I suspect we can get to product for agvhd and chf without a second trial (or have it as a post marketing commitment) - similarly, I suspect we will get eua for some patient groups in covid ards once analysis is complete